Research And Markets Research And Markets

Ghrelin: Pharmaceutical and Therapeutic Opportunities for the Treatment of Obesity

  • ID: 29999
  • August 2003
  • Lead Discovery
1 of 3

It is estimated that somewhere between 34 and 61 million people in the US are obese and in much of the developing world this incidence is increasing by about 1% per year. As a general guide, obesity increases the likelihood of death from all causes by 20%, and plays a major role in the development of coronary heart disease, stroke, diabetes and gall bladder disease. Following the withdrawal of early treatments, the market for anti-obesity pharmaceuticals was reestablished in November 1997, when the FDA approved Abbott's sibutramine (Reductil/Meridia), for use in obesity, and still further in April 1999, when Roche's Xenical (orlistat) was also approved. The world obesity market has been predicted to reach $3.7 billion by 2008 with a compound annual growth rate of 21.1%. This market potential has caused pharmaceutical companies to prioritize the identification of novel anti-obesity products and consequently the number of drugs in development has risen 3-fold over the past 7 years largely due to an increase in preclinical research activities. Pharmaceutical classes receiving greatest attention include 5-HT modulating drugs beta 3 adrenoreceptor agonists lipase inhibitors melanocortin READ MORE >

Note: Product cover images may vary from those shown
2 of 3

<B>Table of contents</B><BR><BR>Astract<BR><BR>Proof of Concept<BR>- An overview of obesity <BR>- The discovery of a novel growth hormone secretagogue receptor (GHS-R) <BR>- The identification of Ghrelin, an endogenous ligand for GHS-R <BR>- Ghrelin as a target for obesity <BR>- Separating orexigenic and GH releasing properties of GHS-R ligands: <BR>- Ghrelin as a target for diabetes <BR>- Ghrelin as a target for cancer <BR><BR>Side Effect risks <BR><BR>Disease incidence and market values <BR><BR>Current development activity<BR>- Key pharmacological targets under investigation as targets for obesity treatments <BR>- Ghrelin related candidates in development <BR>- A comparison of ghrelin with other targets for the treatment of obesity <BR>- Industrial field leaders <BR>- Patent activity relevant to ghrelin<BR><BR>Strategic overview <BR><BR>Screening tools <BR><BR>Academic experts

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown